Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Albendazole

FDA-approved product (tablet, oral), marketed as Albendazole, Albenza.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Albendazole
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cysticercosis
  • Helminthiasis
  • Infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Benzimidazole derivatives
FDA pharmacologic class
Anthelmintic FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC P02CA03; FDA class Anthelmintic

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA32.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli35.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae11.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis40.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Albendazole in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Albendazole with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Schistosome and Intestinal Worm Infections and Malaria Morbidity Among School and Pre-school Children in, Tanzania

    NCT00347113 · start 2006-07

    Registered record
    Registry ID
    NCT00347113
    Conditions
    Anaemia; Malaria; Hepatosplenomegaly
    Interventions
    Albendazole and praziquantel
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2006-07
    Completion
    2011-01
    Enrolment
    620

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnaemia; Malaria; Hepatosplenomegaly
    InterventionAlbendazole and praziquantel
    PhaseNot applicable
    Registry statusCompleted

  • Efficacy Albendazole and Levamisole Against STH on Unguja

    NCT00659997 · start 2006-06

    Registered record
    Registry ID
    NCT00659997
    Conditions
    Ascariasis; Trichuriasis
    Interventions
    Albendazole; Levamisole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-06
    Completion
    2007-09
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAscariasis; Trichuriasis
    InterventionAlbendazole; Levamisole
    PhasePhase 4
    Registry statusCompleted

  • Corticosteroids to Reduce Frequency of Seizures in Neurocysticercosis Patients

    NCT00290823 · start 2006-04

    Registered record
    Registry ID
    NCT00290823
    Conditions
    Neurocysticercosis
    Interventions
    Albendazole; Dexamethasone; Omeprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-04
    Completion
    2011-03
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeurocysticercosis
    InterventionAlbendazole; Dexamethasone; Omeprazole
    PhasePhase 3
    Registry statusCompleted

  • A Pilot Study of Neurocysticercosis Treatment

    NCT00283699 · start 2001-02

    Registered record
    Registry ID
    NCT00283699
    Conditions
    Neurocysticercosis
    Interventions
    albendazole; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-02
    Completion
    2005-02
    Enrolment
    178

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeurocysticercosis
    Interventionalbendazole; placebo
    PhasePhase 3
    Registry statusCompleted

  • Deworming and Vitamin A (DEVTA) Prepilot Study

    NCT00396500 · start 1994-04

    Registered record
    Registry ID
    NCT00396500
    Conditions
    Malnutrition; Worm Infestation; Under-Fives
    Interventions
    Albendazole (400 mg) and/or Vitamin a
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1994-04
    Completion
    1996-12
    Enrolment
    4,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalnutrition; Worm Infestation; Under-Fives
    InterventionAlbendazole (400 mg) and/or Vitamin a
    PhasePhase 3
    Registry statusCompleted